LAVVAN is led by one of the most influential, respected and pioneering teams in the global cannabis industry. After the $2.5 billion purchase of MedReleaf Corp. – a company that from 2014 to 2018 was one of the largest legal producers of cannabinoids in the world – the team dedicated itself to once again revolutionizing the industry that it helped to birth, by bringing to it a level of quality, reliability and sustainability that global brands, manufacturers and suppliers can depend on.
Chief Executive Officer
Dr. Jeremy N. Friedberg
Chief Science Officer
SVP, Regulatory Affairs & Quality Assurance
SVP, Corporate Development
Jason Fleming, CHRE
VP, Human Resources
Senior Advisor, Product Strategy
Director, Product Development
Director, Process Sciences
In March 2019, LAVVAN formed a technology partnership with Amyris (NASDAQ:AMRS), a leader in the development and production of sustainable ingredients for the health and wellness, clean beauty, and flavors and fragrances markets. Amyris has been a global player for over 10 years, leveraging its proprietary process of bio-synthetically engineering organisms to develop custom molecules that produce better, more effective products for both people and the planet.